209 related articles for article (PubMed ID: 16954722)
21. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J
Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863
[TBL] [Abstract][Full Text] [Related]
22. Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
van Heeswijk RP; Bourbeau M; Campbell P; Seguin I; Chauhan BM; Foster BC; Cameron DW
J Clin Pharmacol; 2006 Jul; 46(7):758-67. PubMed ID: 16809801
[TBL] [Abstract][Full Text] [Related]
23. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.
Busti AJ; Bain AM; Hall RG; Bedimo RG; Leff RD; Meek C; Mehvar R
J Cardiovasc Pharmacol; 2008 Jun; 51(6):605-10. PubMed ID: 18520949
[TBL] [Abstract][Full Text] [Related]
24. Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.
Yan Q; Hruz PW
J Acquir Immune Defic Syndr; 2005 Dec; 40(4):398-403. PubMed ID: 16280693
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite.
Verbesselt R; Van Wijngaerden E; de Hoon J
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jan; 845(1):51-60. PubMed ID: 16997640
[TBL] [Abstract][Full Text] [Related]
26. Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection.
Dailly E; Raffi F; Jolliet P
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 813(1-2):353-8. PubMed ID: 15556553
[TBL] [Abstract][Full Text] [Related]
27. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F
AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877
[TBL] [Abstract][Full Text] [Related]
28. HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism.
Kim RJ; Wilson CG; Wabitsch M; Lazar MA; Steppan CM
Obesity (Silver Spring); 2006 Jun; 14(6):994-1002. PubMed ID: 16861604
[TBL] [Abstract][Full Text] [Related]
29. [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
Bernal E; Masiá M; Padilla S; Ramos JM; Martín-Hidalgo A; Gutiérrez F
Med Clin (Barc); 2007 Jul; 129(7):252-4. PubMed ID: 17683706
[TBL] [Abstract][Full Text] [Related]
30. Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
Vernochet C; Azoulay S; Duval D; Guedj R; Ailhaud G; Dani C
AIDS; 2003 Oct; 17(15):2177-80. PubMed ID: 14523274
[TBL] [Abstract][Full Text] [Related]
31. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.
Song I; Min SS; Borland J; Lou Y; Chen S; Patel P; Ishibashi T; Piscitelli SC
J Clin Pharmacol; 2011 Feb; 51(2):237-42. PubMed ID: 20489027
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
van der Lee M; Sankatsing R; Schippers E; Vogel M; Fätkenheuer G; van der Ven A; Kroon F; Rockstroh J; Wyen C; Bäumer A; de Groot E; Koopmans P; Stroes E; Reiss P; Burger D
Antivir Ther; 2007; 12(7):1127-32. PubMed ID: 18018771
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
McRae M; Clay PG; Anderson PL; Glaros AG
Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
[TBL] [Abstract][Full Text] [Related]
34. Application of a rapid and selective method for the simultaneous determination of protease inhibitors, lopinavir and ritonavir in human plasma by UPLC-ESI-MS/MS for bioequivalence study in Indian subjects.
Yadav M; Rao R; Kurani H; Singhal P; Goswami S; Shrivastav PS
J Pharm Biomed Anal; 2009 May; 49(4):1115-22. PubMed ID: 19282124
[TBL] [Abstract][Full Text] [Related]
35. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
[TBL] [Abstract][Full Text] [Related]
36. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
[TBL] [Abstract][Full Text] [Related]
37. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
[TBL] [Abstract][Full Text] [Related]
38. Lopinavir co-induces insulin resistance and ER stress in human adipocytes.
Djedaini M; Peraldi P; Drici MD; Darini C; Saint-Marc P; Dani C; Ladoux A
Biochem Biophys Res Commun; 2009 Aug; 386(1):96-100. PubMed ID: 19501568
[TBL] [Abstract][Full Text] [Related]
39. Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.
van Luin M; Van der Ende ME; Richter C; Visser M; Faraj D; Van der Ven A; Gelinck L; Kroon F; Wit FW; Van Schaik RH; Kuks PF; Burger DM
AIDS; 2010 May; 24(8):1223-6. PubMed ID: 20299957
[TBL] [Abstract][Full Text] [Related]
40. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.
Lee GA; Rao M; Mulligan K; Lo JC; Aweeka F; Schwarz JM; Schambelan M; Grunfeld C
AIDS; 2007 Oct; 21(16):2183-90. PubMed ID: 18090045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
